Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nevirapine misinformation: will it kill?

John S James

    IAPAC Monthly
    |May 17, 2005
    PubMed
    Summary
    This summary is machine-generated.

    Media reports falsely questioned nevirapine (NVP), a vital drug preventing mother-to-child HIV transmission. This misinformation risks undertreatment for HIV-positive mothers, potentially increasing infant infections.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Activism and online fundraising: overview.

    AIDS treatment news·2007
    Same author

    "Fundathon": toward massively multiplayer online fundraising games.

    AIDS treatment news·2007
    Same author

    Selling digital art in bulk through prepaid URLs.

    AIDS treatment news·2007
    Same author

    Financial accounts that can reproduce, inherit, and evolve.

    AIDS treatment news·2007
    Same author

    AIDS search engine wanted: what to do now?

    AIDS treatment news·2007
    Same author

    Prisoner death rate very high immediately after release.

    AIDS treatment news·2007
    Same journal

    PEG-IFN, RBV dosing during chronic HCV re-treatment.

    IAPAC monthly·2007
    Same journal

    Risks higher in GTI at higher CD4 threshold.

    IAPAC monthly·2007
    Same journal

    Mixed co-receptor use associated with lower CD4 count.

    IAPAC monthly·2007
    Same journal

    Focus on hepatitis. HIV/HCV coinfection and CVD risk.

    IAPAC monthly·2007
    Same journal

    Frequent methamphetamine use, primary NNRTI resistance.

    IAPAC monthly·2007
    Same journal

    Delaying maternal NVP-based ART more effective.

    IAPAC monthly·2007
    See all related articles

    Area of Science:

    • Reproductive Health
    • Infectious Disease Prevention
    • Pharmacology

    Background:

    • Associated Press reports in December 2004 inaccurately cast doubt on nevirapine (NVP), a crucial medication for preventing perinatal HIV transmission.
    • These reports stemmed from a personal dispute, not new scientific findings regarding NVP's efficacy or safety.
    • The HIVNET 012 trial in Uganda (1997-1999) provided the initial data on NVP's effectiveness.

    Discussion:

    • Misinformation surrounding NVP risks leading HIV-positive mothers to forgo treatment, thereby increasing the rate of mother-to-child HIV transmission.
    • The controversy highlights the impact of media narratives on public health decisions, particularly concerning established treatments.
    • Experts express concern that emotional responses to flawed reporting will override evidence-based medical recommendations.

    Related Experiment Videos

    Key Insights:

    • Nevirapine (NVP) remains a critical intervention for preventing HIV transmission from mother to child.
    • The risks and benefits of NVP have not changed despite the media reports.
    • The controversy underscores the importance of accurate reporting on medical interventions.

    Outlook:

    • Continued education for healthcare providers and the public is essential to counteract misinformation about NVP.
    • Maintaining trust in evidence-based treatments is crucial for effective HIV prevention strategies.
    • Future research and communication must prioritize clarity and scientific accuracy to prevent undue public alarm.